Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

ash.confex.com

Oral and Poster Abstracts Oral 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Innovative induction regimens in AML: data from real life and clinical trials Clinical Trials, Biological, Adults, AML, Non-Biological, Clinical Research, Chemotherapy, Diseases, Therapies, Myeloid Malignancies, Monoclonal Antibody...

  • A RTC which replaced anthracycline in 7+3 with gemtuzumab for older denovo AML patients did not improve outcomes and had increased toxicity. A reminder that ADC / Targeted therapeutics do not always trump conventional chemotherapy.